Viking Therapeutics presented new exploratory data from its Phase 2 VENTURE trial at ObesityWeek 2026. The analysis revealed that 74% of participants treated with subcutaneous VK2735 improved by at least one BMI category after 13 weeks, compared to 15% for the placebo group. These patients also showed significant improvements in cardiometabolic markers, including blood pressure, glucose, and waist circumference.
An exploratory post-hoc analysis of the already-reported Phase 2 VENTURE trial shows 74% of subcutaneous VK2735 patients improved by at least one BMI category versus 15% on placebo, with improvements in blood pressure, lipids, glucose and waist circumference after 13 weeks. This supports the obesity franchise narrative but adds no new trial data, guidance or milestone beyond previously announced 14.7% weight-loss results, so it is supportive context rather than a material change in outlook.